The trajectory of Sildenafil presents a complex picture for investors. While the initial launch generated substantial profits, the expiration of its exclusive rights opened the avenue to generic versions, dramatically https://bookmarkingbay.com/story21615054/sildenafil-and-big-pharma-a-risky-investment